These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24691833)

  • 1. [Cardiovascular pharmacotherapy. Risks and adverse effects].
    Voigt N; Heijman J; Dobrev D
    Herz; 2014 Mar; 39(2):227-38; quiz 239-40. PubMed ID: 24691833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Manifestation and prevention of adverse drug reactions (ADR) in the pharmacotherapy of cardiovascular diseases].
    Teweleit S; Kuschel U; Hippius M; Goettler M; Bornschein B
    Med Klin (Munich); 2001 Aug; 96(8):442-50. PubMed ID: 11560044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors.
    Fabritz L; Kirchhof P
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):263-8. PubMed ID: 20470256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases.
    Kasper S
    Int J Psychiatry Clin Pract; 2019 Jun; 23(2):134-148. PubMed ID: 30707042
    [No Abstract]   [Full Text] [Related]  

  • 6. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug-drug interactions you should know!].
    Voigt N; Ort K; Sossalla S
    Dtsch Med Wochenschr; 2019 Feb; 144(4):264-275. PubMed ID: 30703807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of therapy of heart diseases in old age].
    Lang E; Wittmann G
    Z Gerontol; 1991; 24(4):171-8. PubMed ID: 1950082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced cardiovascular disorders.
    Mukherjee S; Kar M
    J Assoc Physicians India; 1994 Apr; 42(4):306-8. PubMed ID: 7860550
    [No Abstract]   [Full Text] [Related]  

  • 10. Is antiarrhythmic treatment in the elderly different? a review of the specific changes.
    Deneer VH; van Hemel NM
    Drugs Aging; 2011 Aug; 28(8):617-33. PubMed ID: 21812498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.
    De Ponti F; Poluzzi E; Montanaro N
    Eur J Clin Pharmacol; 2000 Apr; 56(1):1-18. PubMed ID: 10853872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug-drug Interactions You Should Know!].
    Voigt N; Ort K; Sossalla S
    Pneumologie; 2019 May; 73(5):306-318. PubMed ID: 31083751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-drug interactions you should know!].
    Voigt N; Ort K; Sossalla S
    Fortschr Neurol Psychiatr; 2019 May; 87(5):320-332. PubMed ID: 31125990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.
    Giudicessi JR; Ackerman MJ; Camilleri M
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13302. PubMed ID: 29441683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
    Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
    Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiac effects of antidepressant agents].
    Holm H; Luutonen S; Porela P
    Duodecim; 2001; 117(13):1305-10. PubMed ID: 12184118
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women.
    Schwartz JB
    Cardiol Rev; 2003; 11(5):275-98. PubMed ID: 12943605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.